Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts,from 2002 to 2008 and from 2008 to 2014. A population-based study

Abstract

Background

The aim of our study was to evaluate whether treatments for peripheral artery disease changed in two different cohorts identified in 2002 and 2008, and whether this had an impact on mortality and major clinical outcomes after six years of follow-up.

Methods

Using administrative health databases of the largest region in Northern Italy, we identified patients admitted to hospital for peripheral artery disease in 2002 and 2008. Both cohorts were followed for six years. All cause death, acute coronary syndrome, stroke and major amputations, cardiovascular prevention drugs and revascularization procedures were collected. Incidence of events was plotted using adjusted cumulative incidence function estimates. The risk, for each outcome, was compared between 2002–2008 and 2008–2014 using a multivariable Fine and Gray’s semiparametric proportional subdistribution hazards model.

Results

In 2002 and 2008, 2885 and 2848 patients were identified. Adjusting for age, sex, Charlson comorbidity index and severity of peripheral artery disease we observed a significant reduction (in 2008 vs. 2002) in the risk of acute coronary syndrome (28%), stroke (27%) and major amputation (17%). No change was observed in the risk of death. The percentages of patients with peripheral artery revascularizations, during the hospital stay, increased: 43.8% in 2002 vs. 49.0% in 2008, p < 0.001. From 2002 to 2008 there was a significant absolute increase in the prescription of lipid-lowering drugs (+18%), antiplatelets (+7.2%) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (+11.8%), p < 0.001.

Conclusions

In six years of follow-up we observed a reduction in risk of major cardiovascular events in 2008–2014 in comparison with the 2002–2008 cohort. Increasing use of revascularization interventions and cardiovascular prevention drugs could have contributed to the better prognosis.

Keywords

Peripheral arterial disease mortality cardio-cerebrovascular events revascularization

Get full access to this article

View all access options for this article.

References

Skelly

Cifu

. Screening, evaluation, and treatment of peripheral arterial disease. JAMA 2016; 316: 1486–1487.

Fowkes

FGR

Rudan

et al.

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013; 382: 1329–1340.

Price

Mowbray

Lee

et al.

Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999; 20: 344–353.

McDermott

Greenland

Liu

et al.

Leg symptoms in peripheral arterial disease: Associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599–1606.

Golomb

Dang

Criqui

. Peripheral arterial disease: Morbidity and mortality implications. Circulation 2006; 114: 688–699.

Vaartjes

de Borst

Reitsma

et al.

Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities. BMC Cardiovasc Disord 2009; 9: 43–43.

Hosaka

Miyata

Onishi

et al.

Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan. Clin Ther 2014; 36: 1223–1230, 1230.e1-4.

Saw

Bhatt

Moliterno

et al.

The influence of peripheral arterial disease on outcomes: A pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 2006; 48: 1567–1572.

Cea Soriano

Fowkes

FGR

Johansson

et al.

Cardiovascular outcomes for patients with symptomatic peripheral artery disease: A cohort study in The Health Improvement Network (THIN) in the UK. Eur J Prev Cardiol 2017; 18: 1927–1937.

10.

European Stroke Organisation

Tendera

Aboyans

et al.

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–2906.

11.

Gerhard-Herman

Gornik

Barrett

et al.

2016 AHA/ACC lower extremity PAD Guideline: Executive Summary. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135: e686–e725.

12.

Dopheide

Rubrech

Trumpp

et al.

Supervised exercise training in peripheral arterial disease increases vascular shear stress and profunda femoral artery diameter. Eur J Prev Cardiol 2017; 2: 178–191.

13.

Subherwal

Patel

Kober

et al.

Missed opportunities: Despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 2012; 126: 1345–1354.

14.

Kirchberger

Amann

Heier

et al.

Presenting symptoms, pre-hospital delay time and 28-day case fatality in patients with peripheral arterial disease and acute myocardial infarction from the MONICA/KORA Myocardial Infarction Registry. Eur J Prev Cardiol 2017; 3: 265–273.

15.

Sigvant

Wiberg-Hedman

Bergqvist

et al.

Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2009; 16: 39–46.

16.

Sharma

Thapa

Jeevanantham

et al.

Comparison of lipid management in patients with coronary versus peripheral arterial disease. Am J Cardiol 2014; 113: 1320–1325.

17.

Müller-Bühl

Laux

Szecsenyi

. Secondary pharmacotherapeutic prevention among German primary care patients with peripheral arterial disease. Int J Vasc Med 2011; 2011: 316496–316496.

18.

Sigvant

Lundin

Wahlberg

. The risk of disease progression in peripheral arterial disease is higher than expected: A meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 2016; 51: 395–403.

19.

Feringa

van Waning

Bax

et al.

Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47: 1182–1187.

20.

Høgh

Lindholt

Nielsen

et al.

Secondary medical prevention after primary vascular surgery between 1996 and 2006: A shift towards more evidence-based treatment. Eur J Prev Cardiol 2013; 20: 763–770.

21.

D’Hoore

Bouckaert

Tilquin

. Practical consideration on the use of Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429–1433.

22.

Collins

Armitage

Parish

et al.

Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005–2016.

23.

Yusuf

Sleight

Pogue

et al.

Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

24.

ONTARGET Investigators

Yusuf

Teo

et al.

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB